Advanced Unresectable Clinical Trials

35 recruitingLast updated: July 25, 2026

There are 35 actively recruiting advanced unresectable clinical trials across 25 countries. Studies span Phase 2, Phase 1, Phase 3. Top locations include New York, New York, United States, Nashville, Tennessee, United States, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Advanced Unresectable Trials at a Glance

35 actively recruiting trials for advanced unresectable are listed on ClinicalTrialsFinder across 6 cities in 25 countries. The largest study group is Phase 2 with 21 trials, with the heaviest enrollment activity in New York, Nashville, and Houston. Lead sponsors running advanced unresectable studies include Innovent Biologics (Suzhou) Co. Ltd., NEOK Bio, Inc., and Shandong Suncadia Medicine Co., Ltd..

Browse advanced unresectable trials by phase

Treatments under study

About Advanced Unresectable Clinical Trials

Looking for clinical trials for Advanced Unresectable? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Advanced Unresectable trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Advanced Unresectable clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 35 trials

Recruiting
Phase 2

A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States

Esophageal Squamous Cell CarcinomaAdvanced Unresectable Gastric AdenocarcinomaAdvanced Gastroesophageal Adenocarcinoma
BeOne Medicines30 enrolled6 locationsNCT07554521
Recruiting
Phase 1Phase 2

A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients

Advanced Unresectable or Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.528 enrolled1 locationNCT06555068
Recruiting
Phase 1

SG1906 for CLDN18.2-Positive Solid Tumors

Locally Advanced Unresectable or Metastatic Solid Tumors
Hangzhou Sumgen Biotech Co., Ltd.60 enrolled9 locationsNCT05857332
Recruiting

A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Korea, Inc.377 enrolled13 locationsNCT06902545
Recruiting
Phase 3

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc.500 enrolled249 locationsNCT06901531
Recruiting
Phase 3

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8+1 more
NRG Oncology356 enrolled322 locationsNCT06958328
Recruiting
Phase 1Phase 2

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+97 more
Mayo Clinic132 enrolled1 locationNCT05269381
Recruiting
Phase 2

Neoadjuvant Tebentafusp for Uveal Melanoma

Locally Advanced Unresectable Uveal Melanoma
Thomas Jefferson University19 enrolled2 locationsNCT06414590
Recruiting
Phase 2

SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors

Locally Advanced Unresectable or Metastatic Solid Tumors
Shenyang Sunshine Pharmaceutical Co., LTD.150 enrolled1 locationNCT07646626
Recruiting
Phase 1

A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors

Locally Advanced Unresectable or Metastatic Solid Tumors
NEOK Bio, Inc.155 enrolled8 locationsNCT07612189
Recruiting
Phase 1

A Phase 1 Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors

Locally Advanced Unresectable or Metastatic Solid Tumors
NEOK Bio, Inc.155 enrolled8 locationsNCT07612176
Recruiting
Phase 1

A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma

Advanced Unresectable Hepatocellular Carcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.36 enrolled2 locationsNCT07478302
Recruiting
Phase 1

A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Locally Advanced Unresectable or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.470 enrolled39 locationsNCT05458219
Recruiting
Phase 2

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+1 more
Roswell Park Cancer Institute30 enrolled1 locationNCT06434064
Recruiting
Phase 2

Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma

Advanced Unresectable Hepatocellular Carcinoma
Riboscience, LLC.220 enrolled4 locationsNCT07175441
Recruiting

A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)

Locally Advanced Unresectable or Metastatic Gastric Cancer
Akeso610 enrolled1 locationNCT07547787
Recruiting
Phase 2

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic HER2-Negative Breast Carcinoma+3 more
University of Washington60 enrolled2 locationsNCT06179303
Recruiting
Phase 2

Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC

Esophageal Squamous Cell CarcinomaLocally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Sichuan University118 enrolled1 locationNCT07519486
Recruiting
Phase 2

Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Ning Jiang, M.D./Ph.D.98 enrolled1 locationNCT07530094
Recruiting
Phase 1Phase 2

Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors

MetastaticAdvanced Unresectable
Beijing Biotech72 enrolled1 locationNCT07523529